Dupilumab, a monoclonal antibody, is administered in the form of injection for the treatment of Atopic dermatitis (Eczema) in adults and children of age 12 and old. The injection works by hampering the substance in the body, which produces allergic reactions. Dupilumab is a receptor-antagonist and binds to the alpha subunit of the interleukin-4 receptor (IL-4Rα). The blockade of IL-4Rα, signalling of both the interleukin 4 and interleukin 13 pathways. 

The injection is sold under the brand name Dupixent, and the drug is also given in combination with other medications to prevent wheezing, shortness of breath, coughing, and chest tightness due to certain types of asthma. Moreover, the injection is also administered to treat chronic rhinosinusitis with nasal polyposis in adults. 

Dupilumab is the only therapy present in the Atopic dermatitis market that targets the IL-4/IL-13 pathway, a key driver of allergies and inflammation type 2. 

There are companies developing therapies to advance Atopic dermatitis market. Companies like Galderma Pharma, LEO Pharma, Roviant Sciences, and many others are developing drugs to fuel the Atopic dermatitis market. However, DelveInsight’s analysts estimate that Dupilumab is likely to rule in the Atopic dermatitis market. 

For any other drug candidate to receive investigational therapy, the drug should be able to prove the drug in question, i.e., Dupilumab inferior. The novel drug should be able to have an improved dosing and a convenient administration method. 

Moreover, the new drug should be able to score higher points in the Eczema Area and Severity Index (EASI) or Investigator’s Global Assessment (IGA) primary endpoint scoring systems. 

However, Atopic dermatitis upcoming therapies hold the potential to supersede the existing treatments and occupy a significant share of the market.